Drug Trial Radar · NCT03563157
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Last checked: Nov 20, 2026Latest source record: Dec 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Sep 28, 2018
Primary completion
Apr 21, 2019
Study completion Aug 21, 2019
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
Conditions
- Colorectal Cancer Metastatic
- mCRC
Interventions
Aldoxorubicin HydrochlorideBiological
Aldoxorubicin Hydrochloride HCI
ALT-803Biological
Recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1\]
ETBX-011Biological
Ad5 \[E1-, E2b-\]-CEA
ETBX-021Biological
Ad5 \[E1-, E2b-\]-\[HER2\]
ETBX-051Biological
Ad5 \[E1-, E2b-\]-Brachyury
ETBX-061Biological
Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
GI-4000Biological
RAS yeast
GI-6207Biological
CEA yeast
GI-6301Biological
Brachyury yeast
haNKBiological
haNK™, NK-92 \[CD16.158V, ER IL-2\]
AvelumabDrug
BAVENCIO® injection
CapecitabineDrug
XELODA® tablets
CetuximabDrug
ERBITUX® injection
CyclophosphamideDrug
Cyclophosphamide Capsules
5-FluorouracilDrug
5-FU; Fluorouracil Injection
LeucovorinDrug
Leucovorin Calcium
Nab-paclitaxelDrug
ABRAXANE® for Injectable Suspension \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
OxaliplatinDrug
ELOXATIN® injection
RegorafenibDrug
STIVARGA® tablets
SBRTProcedure
Stereotactic body radiation therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: 30 days after last dose, up to 6 months or until they experience confirmed progressive disease or unacceptable toxicity, withdrawn consent, or if the Investigator feels it is no longer in their best interest.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.